nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—ABCB1—colon cancer	0.309	1	CbGaD
Lansoprazole—ABCG2—Irinotecan—colon cancer	0.0609	0.154	CbGbCtD
Lansoprazole—ABCG2—Fluorouracil—colon cancer	0.0585	0.148	CbGbCtD
Lansoprazole—ABCG2—Vincristine—colon cancer	0.0533	0.134	CbGbCtD
Lansoprazole—CYP2C9—Capecitabine—colon cancer	0.0367	0.0925	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—colon cancer	0.0323	0.0814	CbGbCtD
Lansoprazole—CYP2C8—Fluorouracil—colon cancer	0.0312	0.0787	CbGbCtD
Lansoprazole—CYP1A2—Fluorouracil—colon cancer	0.0241	0.0609	CbGbCtD
Lansoprazole—ABCB1—Irinotecan—colon cancer	0.022	0.0555	CbGbCtD
Lansoprazole—CYP2C9—Fluorouracil—colon cancer	0.0217	0.0549	CbGbCtD
Lansoprazole—ABCB1—Vincristine—colon cancer	0.0192	0.0485	CbGbCtD
Lansoprazole—CYP3A4—Irinotecan—colon cancer	0.0132	0.0332	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—colon cancer	0.0116	0.0294	CbGbCtD
Lansoprazole—CYP3A4—Vincristine—colon cancer	0.0115	0.0291	CbGbCtD
Lansoprazole—ATP4B—digestive system—colon cancer	0.00392	0.0854	CbGeAlD
Lansoprazole—ATP4B—liver—colon cancer	0.00292	0.0636	CbGeAlD
Lansoprazole—CYP4A11—renal system—colon cancer	0.00258	0.0562	CbGeAlD
Lansoprazole—ATP4A—epithelium—colon cancer	0.00225	0.0488	CbGeAlD
Lansoprazole—CYP4A11—digestive system—colon cancer	0.00212	0.0461	CbGeAlD
Lansoprazole—ATP4A—renal system—colon cancer	0.00208	0.0453	CbGeAlD
Lansoprazole—CYP4A11—vagina—colon cancer	0.00187	0.0407	CbGeAlD
Lansoprazole—ATP4A—digestive system—colon cancer	0.00171	0.0372	CbGeAlD
Lansoprazole—CYP4A11—liver—colon cancer	0.00158	0.0343	CbGeAlD
Lansoprazole—CYP2C18—digestive system—colon cancer	0.0014	0.0305	CbGeAlD
Lansoprazole—MAPT—lymph node—colon cancer	0.00131	0.0286	CbGeAlD
Lansoprazole—ATP4A—liver—colon cancer	0.00127	0.0277	CbGeAlD
Lansoprazole—CYP2C18—vagina—colon cancer	0.00124	0.027	CbGeAlD
Lansoprazole—CYP2C18—liver—colon cancer	0.00105	0.0227	CbGeAlD
Lansoprazole—CYP1B1—smooth muscle tissue—colon cancer	0.000861	0.0187	CbGeAlD
Lansoprazole—CYP1B1—renal system—colon cancer	0.000829	0.018	CbGeAlD
Lansoprazole—Pantoprazole—ABCB1—colon cancer	0.000693	0.551	CrCbGaD
Lansoprazole—CYP1B1—lymphoid tissue—colon cancer	0.000688	0.015	CbGeAlD
Lansoprazole—CYP1B1—digestive system—colon cancer	0.00068	0.0148	CbGeAlD
Lansoprazole—ABCB1—blood vessel—colon cancer	0.000674	0.0147	CbGeAlD
Lansoprazole—CYP2C8—renal system—colon cancer	0.000635	0.0138	CbGeAlD
Lansoprazole—CYP1A1—epithelium—colon cancer	0.000632	0.0137	CbGeAlD
Lansoprazole—CYP2C19—digestive system—colon cancer	0.000597	0.013	CbGeAlD
Lansoprazole—CYP1A2—renal system—colon cancer	0.000594	0.0129	CbGeAlD
Lansoprazole—CYP1A1—renal system—colon cancer	0.000586	0.0127	CbGeAlD
Lansoprazole—Omeprazole—ABCB1—colon cancer	0.000565	0.449	CrCbGaD
Lansoprazole—CYP2C19—vagina—colon cancer	0.000527	0.0115	CbGeAlD
Lansoprazole—CYP1B1—liver—colon cancer	0.000507	0.011	CbGeAlD
Lansoprazole—CYP1A2—digestive system—colon cancer	0.000487	0.0106	CbGeAlD
Lansoprazole—CYP1A1—digestive system—colon cancer	0.000481	0.0105	CbGeAlD
Lansoprazole—ABCG2—bone marrow—colon cancer	0.000467	0.0102	CbGeAlD
Lansoprazole—CYP2C9—digestive system—colon cancer	0.000463	0.0101	CbGeAlD
Lansoprazole—CYP2C8—vagina—colon cancer	0.00046	0.01	CbGeAlD
Lansoprazole—ABCG2—vagina—colon cancer	0.000447	0.00973	CbGeAlD
Lansoprazole—CYP2C19—liver—colon cancer	0.000445	0.00967	CbGeAlD
Lansoprazole—CYP3A4—renal system—colon cancer	0.00043	0.00935	CbGeAlD
Lansoprazole—CYP1A1—vagina—colon cancer	0.000425	0.00923	CbGeAlD
Lansoprazole—CYP2D6—renal system—colon cancer	0.000423	0.00921	CbGeAlD
Lansoprazole—ABCB1—embryo—colon cancer	0.000402	0.00875	CbGeAlD
Lansoprazole—CYP1B1—lymph node—colon cancer	0.000388	0.00845	CbGeAlD
Lansoprazole—CYP2C8—liver—colon cancer	0.000388	0.00844	CbGeAlD
Lansoprazole—ABCG2—liver—colon cancer	0.000377	0.00821	CbGeAlD
Lansoprazole—CYP1A2—liver—colon cancer	0.000363	0.0079	CbGeAlD
Lansoprazole—CYP1A1—liver—colon cancer	0.000358	0.00779	CbGeAlD
Lansoprazole—CYP3A4—digestive system—colon cancer	0.000353	0.00767	CbGeAlD
Lansoprazole—CYP2D6—digestive system—colon cancer	0.000347	0.00755	CbGeAlD
Lansoprazole—CYP2C9—liver—colon cancer	0.000345	0.0075	CbGeAlD
Lansoprazole—ABCB1—epithelium—colon cancer	0.000328	0.00714	CbGeAlD
Lansoprazole—ABCB1—renal system—colon cancer	0.000304	0.00662	CbGeAlD
Lansoprazole—ABCG2—lymph node—colon cancer	0.000289	0.00629	CbGeAlD
Lansoprazole—CYP1A1—lymph node—colon cancer	0.000275	0.00597	CbGeAlD
Lansoprazole—CYP3A4—liver—colon cancer	0.000263	0.00572	CbGeAlD
Lansoprazole—CYP2D6—liver—colon cancer	0.000259	0.00563	CbGeAlD
Lansoprazole—ABCB1—lymphoid tissue—colon cancer	0.000253	0.0055	CbGeAlD
Lansoprazole—ABCB1—digestive system—colon cancer	0.00025	0.00543	CbGeAlD
Lansoprazole—ABCB1—bone marrow—colon cancer	0.00023	0.00501	CbGeAlD
Lansoprazole—ABCB1—vagina—colon cancer	0.000221	0.0048	CbGeAlD
Lansoprazole—ABCB1—liver—colon cancer	0.000186	0.00405	CbGeAlD
Lansoprazole—Confusional state—Fluorouracil—colon cancer	0.000186	0.000973	CcSEcCtD
Lansoprazole—Mood swings—Methotrexate—colon cancer	0.000185	0.000967	CcSEcCtD
Lansoprazole—Hypotension—Vincristine—colon cancer	0.000185	0.000966	CcSEcCtD
Lansoprazole—Bradycardia—Capecitabine—colon cancer	0.000185	0.000966	CcSEcCtD
Lansoprazole—Anaphylactic shock—Fluorouracil—colon cancer	0.000184	0.000965	CcSEcCtD
Lansoprazole—Oedema—Fluorouracil—colon cancer	0.000184	0.000965	CcSEcCtD
Lansoprazole—Anorexia—Irinotecan—colon cancer	0.000183	0.00096	CcSEcCtD
Lansoprazole—Infection—Fluorouracil—colon cancer	0.000183	0.000958	CcSEcCtD
Lansoprazole—Rhinitis—Capecitabine—colon cancer	0.000182	0.000951	CcSEcCtD
Lansoprazole—Hepatitis—Capecitabine—colon cancer	0.000181	0.000949	CcSEcCtD
Lansoprazole—Nervous system disorder—Fluorouracil—colon cancer	0.000181	0.000946	CcSEcCtD
Lansoprazole—Thrombocytopenia—Fluorouracil—colon cancer	0.00018	0.000944	CcSEcCtD
Lansoprazole—Hypoaesthesia—Capecitabine—colon cancer	0.00018	0.000944	CcSEcCtD
Lansoprazole—Liver function test abnormal—Methotrexate—colon cancer	0.00018	0.000943	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Vincristine—colon cancer	0.00018	0.000942	CcSEcCtD
Lansoprazole—Pharyngitis—Capecitabine—colon cancer	0.00018	0.000942	CcSEcCtD
Lansoprazole—Tachycardia—Fluorouracil—colon cancer	0.00018	0.000941	CcSEcCtD
Lansoprazole—Hypotension—Irinotecan—colon cancer	0.00018	0.000941	CcSEcCtD
Lansoprazole—Urinary tract disorder—Capecitabine—colon cancer	0.000179	0.000937	CcSEcCtD
Lansoprazole—Insomnia—Vincristine—colon cancer	0.000179	0.000935	CcSEcCtD
Lansoprazole—Oedema peripheral—Capecitabine—colon cancer	0.000179	0.000935	CcSEcCtD
Lansoprazole—Connective tissue disorder—Capecitabine—colon cancer	0.000178	0.000932	CcSEcCtD
Lansoprazole—Urethral disorder—Capecitabine—colon cancer	0.000178	0.00093	CcSEcCtD
Lansoprazole—Paraesthesia—Vincristine—colon cancer	0.000177	0.000929	CcSEcCtD
Lansoprazole—Breast disorder—Methotrexate—colon cancer	0.000176	0.000923	CcSEcCtD
Lansoprazole—Anorexia—Fluorouracil—colon cancer	0.000176	0.00092	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000176	0.000919	CcSEcCtD
Lansoprazole—Visual impairment—Capecitabine—colon cancer	0.000175	0.000914	CcSEcCtD
Lansoprazole—Insomnia—Irinotecan—colon cancer	0.000174	0.000911	CcSEcCtD
Lansoprazole—Paraesthesia—Irinotecan—colon cancer	0.000173	0.000904	CcSEcCtD
Lansoprazole—Hypotension—Fluorouracil—colon cancer	0.000172	0.000901	CcSEcCtD
Lansoprazole—Decreased appetite—Vincristine—colon cancer	0.000172	0.000899	CcSEcCtD
Lansoprazole—Dyspnoea—Irinotecan—colon cancer	0.000172	0.000898	CcSEcCtD
Lansoprazole—Erythema multiforme—Capecitabine—colon cancer	0.000171	0.000897	CcSEcCtD
Lansoprazole—Somnolence—Irinotecan—colon cancer	0.000171	0.000895	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Vincristine—colon cancer	0.000171	0.000893	CcSEcCtD
Lansoprazole—Fatigue—Vincristine—colon cancer	0.00017	0.000892	CcSEcCtD
Lansoprazole—Eye disorder—Capecitabine—colon cancer	0.000169	0.000887	CcSEcCtD
Lansoprazole—Dyspepsia—Irinotecan—colon cancer	0.000169	0.000887	CcSEcCtD
Lansoprazole—Tinnitus—Capecitabine—colon cancer	0.000169	0.000885	CcSEcCtD
Lansoprazole—Pain—Vincristine—colon cancer	0.000169	0.000884	CcSEcCtD
Lansoprazole—Constipation—Vincristine—colon cancer	0.000169	0.000884	CcSEcCtD
Lansoprazole—Asthma—Methotrexate—colon cancer	0.000169	0.000882	CcSEcCtD
Lansoprazole—Cardiac disorder—Capecitabine—colon cancer	0.000168	0.000881	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000168	0.000879	CcSEcCtD
Lansoprazole—Decreased appetite—Irinotecan—colon cancer	0.000167	0.000876	CcSEcCtD
Lansoprazole—Eosinophilia—Methotrexate—colon cancer	0.000167	0.000874	CcSEcCtD
Lansoprazole—Insomnia—Fluorouracil—colon cancer	0.000167	0.000872	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Irinotecan—colon cancer	0.000166	0.00087	CcSEcCtD
Lansoprazole—Fatigue—Irinotecan—colon cancer	0.000166	0.000868	CcSEcCtD
Lansoprazole—Paraesthesia—Fluorouracil—colon cancer	0.000166	0.000866	CcSEcCtD
Lansoprazole—Pancreatitis—Methotrexate—colon cancer	0.000165	0.000865	CcSEcCtD
Lansoprazole—Pain—Irinotecan—colon cancer	0.000165	0.000861	CcSEcCtD
Lansoprazole—Constipation—Irinotecan—colon cancer	0.000165	0.000861	CcSEcCtD
Lansoprazole—Angiopathy—Capecitabine—colon cancer	0.000165	0.000861	CcSEcCtD
Lansoprazole—Dyspnoea—Fluorouracil—colon cancer	0.000164	0.00086	CcSEcCtD
Lansoprazole—Somnolence—Fluorouracil—colon cancer	0.000164	0.000858	CcSEcCtD
Lansoprazole—Immune system disorder—Capecitabine—colon cancer	0.000164	0.000857	CcSEcCtD
Lansoprazole—Mediastinal disorder—Capecitabine—colon cancer	0.000163	0.000855	CcSEcCtD
Lansoprazole—Chills—Capecitabine—colon cancer	0.000163	0.000851	CcSEcCtD
Lansoprazole—Dyspepsia—Fluorouracil—colon cancer	0.000162	0.000849	CcSEcCtD
Lansoprazole—Arrhythmia—Capecitabine—colon cancer	0.000162	0.000848	CcSEcCtD
Lansoprazole—Abdominal discomfort—Methotrexate—colon cancer	0.000162	0.000846	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Vincristine—colon cancer	0.000162	0.000846	CcSEcCtD
Lansoprazole—Decreased appetite—Fluorouracil—colon cancer	0.00016	0.000839	CcSEcCtD
Lansoprazole—Alopecia—Capecitabine—colon cancer	0.00016	0.000838	CcSEcCtD
Lansoprazole—Pancytopenia—Methotrexate—colon cancer	0.00016	0.000838	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000159	0.000833	CcSEcCtD
Lansoprazole—Mental disorder—Capecitabine—colon cancer	0.000159	0.000831	CcSEcCtD
Lansoprazole—Feeling abnormal—Irinotecan—colon cancer	0.000159	0.00083	CcSEcCtD
Lansoprazole—Malnutrition—Capecitabine—colon cancer	0.000158	0.000826	CcSEcCtD
Lansoprazole—Erythema—Capecitabine—colon cancer	0.000158	0.000826	CcSEcCtD
Lansoprazole—Dysuria—Methotrexate—colon cancer	0.000158	0.000825	CcSEcCtD
Lansoprazole—Neutropenia—Methotrexate—colon cancer	0.000158	0.000825	CcSEcCtD
Lansoprazole—Pain—Fluorouracil—colon cancer	0.000158	0.000825	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Irinotecan—colon cancer	0.000157	0.000824	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Methotrexate—colon cancer	0.000157	0.00082	CcSEcCtD
Lansoprazole—Abdominal pain—Vincristine—colon cancer	0.000156	0.000818	CcSEcCtD
Lansoprazole—Body temperature increased—Vincristine—colon cancer	0.000156	0.000818	CcSEcCtD
Lansoprazole—Flatulence—Capecitabine—colon cancer	0.000156	0.000814	CcSEcCtD
Lansoprazole—Erectile dysfunction—Methotrexate—colon cancer	0.000155	0.000813	CcSEcCtD
Lansoprazole—Dysgeusia—Capecitabine—colon cancer	0.000155	0.000809	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Methotrexate—colon cancer	0.000154	0.000805	CcSEcCtD
Lansoprazole—Back pain—Capecitabine—colon cancer	0.000153	0.000799	CcSEcCtD
Lansoprazole—Abdominal pain—Irinotecan—colon cancer	0.000152	0.000796	CcSEcCtD
Lansoprazole—Body temperature increased—Irinotecan—colon cancer	0.000152	0.000796	CcSEcCtD
Lansoprazole—Feeling abnormal—Fluorouracil—colon cancer	0.000152	0.000795	CcSEcCtD
Lansoprazole—Muscle spasms—Capecitabine—colon cancer	0.000152	0.000794	CcSEcCtD
Lansoprazole—Pneumonia—Methotrexate—colon cancer	0.000151	0.000791	CcSEcCtD
Lansoprazole—Infestation NOS—Methotrexate—colon cancer	0.00015	0.000787	CcSEcCtD
Lansoprazole—Infestation—Methotrexate—colon cancer	0.00015	0.000787	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000149	0.00078	CcSEcCtD
Lansoprazole—Vision blurred—Capecitabine—colon cancer	0.000149	0.000778	CcSEcCtD
Lansoprazole—Tremor—Capecitabine—colon cancer	0.000148	0.000774	CcSEcCtD
Lansoprazole—Renal failure—Methotrexate—colon cancer	0.000148	0.000773	CcSEcCtD
Lansoprazole—Stomatitis—Methotrexate—colon cancer	0.000147	0.000767	CcSEcCtD
Lansoprazole—Ill-defined disorder—Capecitabine—colon cancer	0.000146	0.000766	CcSEcCtD
Lansoprazole—Urticaria—Fluorouracil—colon cancer	0.000146	0.000766	CcSEcCtD
Lansoprazole—Conjunctivitis—Methotrexate—colon cancer	0.000146	0.000765	CcSEcCtD
Lansoprazole—Anaemia—Capecitabine—colon cancer	0.000146	0.000763	CcSEcCtD
Lansoprazole—Body temperature increased—Fluorouracil—colon cancer	0.000146	0.000763	CcSEcCtD
Lansoprazole—Hypersensitivity—Vincristine—colon cancer	0.000146	0.000762	CcSEcCtD
Lansoprazole—Sweating—Methotrexate—colon cancer	0.000144	0.000754	CcSEcCtD
Lansoprazole—Haematuria—Methotrexate—colon cancer	0.000143	0.00075	CcSEcCtD
Lansoprazole—ABCB1—lymph node—colon cancer	0.000143	0.0031	CbGeAlD
Lansoprazole—Malaise—Capecitabine—colon cancer	0.000142	0.000745	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Methotrexate—colon cancer	0.000142	0.000744	CcSEcCtD
Lansoprazole—Epistaxis—Methotrexate—colon cancer	0.000142	0.000742	CcSEcCtD
Lansoprazole—Vertigo—Capecitabine—colon cancer	0.000142	0.000742	CcSEcCtD
Lansoprazole—Hypersensitivity—Irinotecan—colon cancer	0.000142	0.000742	CcSEcCtD
Lansoprazole—Asthenia—Vincristine—colon cancer	0.000142	0.000742	CcSEcCtD
Lansoprazole—Syncope—Capecitabine—colon cancer	0.000142	0.000741	CcSEcCtD
Lansoprazole—Leukopenia—Capecitabine—colon cancer	0.000141	0.000739	CcSEcCtD
Lansoprazole—Agranulocytosis—Methotrexate—colon cancer	0.00014	0.000734	CcSEcCtD
Lansoprazole—Palpitations—Capecitabine—colon cancer	0.000139	0.00073	CcSEcCtD
Lansoprazole—Loss of consciousness—Capecitabine—colon cancer	0.000139	0.000726	CcSEcCtD
Lansoprazole—Asthenia—Irinotecan—colon cancer	0.000138	0.000723	CcSEcCtD
Lansoprazole—Cough—Capecitabine—colon cancer	0.000138	0.000721	CcSEcCtD
Lansoprazole—Hypertension—Capecitabine—colon cancer	0.000136	0.000713	CcSEcCtD
Lansoprazole—Hypersensitivity—Fluorouracil—colon cancer	0.000136	0.000711	CcSEcCtD
Lansoprazole—Diarrhoea—Vincristine—colon cancer	0.000135	0.000708	CcSEcCtD
Lansoprazole—Hepatitis—Methotrexate—colon cancer	0.000135	0.000706	CcSEcCtD
Lansoprazole—Arthralgia—Capecitabine—colon cancer	0.000134	0.000703	CcSEcCtD
Lansoprazole—Myalgia—Capecitabine—colon cancer	0.000134	0.000703	CcSEcCtD
Lansoprazole—Chest pain—Capecitabine—colon cancer	0.000134	0.000703	CcSEcCtD
Lansoprazole—Pharyngitis—Methotrexate—colon cancer	0.000134	0.000701	CcSEcCtD
Lansoprazole—Anxiety—Capecitabine—colon cancer	0.000134	0.000701	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000133	0.000698	CcSEcCtD
Lansoprazole—Urinary tract disorder—Methotrexate—colon cancer	0.000133	0.000698	CcSEcCtD
Lansoprazole—Discomfort—Capecitabine—colon cancer	0.000133	0.000695	CcSEcCtD
Lansoprazole—Urethral disorder—Methotrexate—colon cancer	0.000132	0.000692	CcSEcCtD
Lansoprazole—Diarrhoea—Irinotecan—colon cancer	0.000132	0.000689	CcSEcCtD
Lansoprazole—Dry mouth—Capecitabine—colon cancer	0.000131	0.000688	CcSEcCtD
Lansoprazole—Dizziness—Vincristine—colon cancer	0.000131	0.000684	CcSEcCtD
Lansoprazole—Pruritus—Fluorouracil—colon cancer	0.00013	0.000682	CcSEcCtD
Lansoprazole—Visual impairment—Methotrexate—colon cancer	0.00013	0.000681	CcSEcCtD
Lansoprazole—Confusional state—Capecitabine—colon cancer	0.00013	0.00068	CcSEcCtD
Lansoprazole—Oedema—Capecitabine—colon cancer	0.000129	0.000674	CcSEcCtD
Lansoprazole—Infection—Capecitabine—colon cancer	0.000128	0.00067	CcSEcCtD
Lansoprazole—Erythema multiforme—Methotrexate—colon cancer	0.000128	0.000668	CcSEcCtD
Lansoprazole—Dizziness—Irinotecan—colon cancer	0.000127	0.000666	CcSEcCtD
Lansoprazole—Shock—Capecitabine—colon cancer	0.000127	0.000663	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000126	0.00223	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000126	0.00223	CbGpPWpGaD
Lansoprazole—Nervous system disorder—Capecitabine—colon cancer	0.000126	0.000661	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—colon cancer	0.000126	0.00066	CcSEcCtD
Lansoprazole—Diarrhoea—Fluorouracil—colon cancer	0.000126	0.00066	CcSEcCtD
Lansoprazole—Thrombocytopenia—Capecitabine—colon cancer	0.000126	0.00066	CcSEcCtD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—TP53—colon cancer	0.000126	0.00222	CbGpPWpGaD
Lansoprazole—Tinnitus—Methotrexate—colon cancer	0.000126	0.000659	CcSEcCtD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000126	0.00222	CbGpPWpGaD
Lansoprazole—Tachycardia—Capecitabine—colon cancer	0.000126	0.000658	CcSEcCtD
Lansoprazole—Vomiting—Vincristine—colon cancer	0.000126	0.000658	CcSEcCtD
Lansoprazole—Cardiac disorder—Methotrexate—colon cancer	0.000125	0.000656	CcSEcCtD
Lansoprazole—Skin disorder—Capecitabine—colon cancer	0.000125	0.000655	CcSEcCtD
Lansoprazole—Rash—Vincristine—colon cancer	0.000125	0.000652	CcSEcCtD
Lansoprazole—Hyperhidrosis—Capecitabine—colon cancer	0.000125	0.000652	CcSEcCtD
Lansoprazole—Dermatitis—Vincristine—colon cancer	0.000124	0.000651	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000124	0.00219	CbGpPWpGaD
Lansoprazole—Headache—Vincristine—colon cancer	0.000124	0.000648	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—MYC—colon cancer	0.000123	0.00217	CbGpPWpGaD
Lansoprazole—Anorexia—Capecitabine—colon cancer	0.000123	0.000643	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—TGFB1—colon cancer	0.000123	0.00217	CbGpPWpGaD
Lansoprazole—Angiopathy—Methotrexate—colon cancer	0.000122	0.000641	CcSEcCtD
Lansoprazole—Vomiting—Irinotecan—colon cancer	0.000122	0.00064	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—colon cancer	0.000122	0.000638	CcSEcCtD
Lansoprazole—Dizziness—Fluorouracil—colon cancer	0.000122	0.000638	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—colon cancer	0.000122	0.000637	CcSEcCtD
Lansoprazole—Rash—Irinotecan—colon cancer	0.000121	0.000635	CcSEcCtD
Lansoprazole—Dermatitis—Irinotecan—colon cancer	0.000121	0.000634	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—CA7—colon cancer	0.000121	0.00214	CbGpPWpGaD
Lansoprazole—Chills—Methotrexate—colon cancer	0.000121	0.000634	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000121	0.00214	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000121	0.00213	CbGpPWpGaD
Lansoprazole—Headache—Irinotecan—colon cancer	0.000121	0.000631	CcSEcCtD
Lansoprazole—Hypotension—Capecitabine—colon cancer	0.00012	0.00063	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—EGFR—colon cancer	0.00012	0.00212	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000119	0.00211	CbGpPWpGaD
Lansoprazole—Alopecia—Methotrexate—colon cancer	0.000119	0.000624	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—colon cancer	0.000118	0.000619	CcSEcCtD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000118	0.00209	CbGpPWpGaD
Lansoprazole—Malnutrition—Methotrexate—colon cancer	0.000118	0.000615	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—colon cancer	0.000118	0.000615	CcSEcCtD
Lansoprazole—Nausea—Vincristine—colon cancer	0.000117	0.000614	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000117	0.000614	CcSEcCtD
Lansoprazole—Vomiting—Fluorouracil—colon cancer	0.000117	0.000613	CcSEcCtD
Lansoprazole—Insomnia—Capecitabine—colon cancer	0.000117	0.00061	CcSEcCtD
Lansoprazole—Rash—Fluorouracil—colon cancer	0.000116	0.000608	CcSEcCtD
Lansoprazole—Dermatitis—Fluorouracil—colon cancer	0.000116	0.000608	CcSEcCtD
Lansoprazole—Paraesthesia—Capecitabine—colon cancer	0.000116	0.000605	CcSEcCtD
Lansoprazole—Headache—Fluorouracil—colon cancer	0.000115	0.000604	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—colon cancer	0.000115	0.000602	CcSEcCtD
Lansoprazole—Dyspnoea—Capecitabine—colon cancer	0.000115	0.000601	CcSEcCtD
Lansoprazole—CYP4A11—PPARA activates gene expression—EP300—colon cancer	0.000115	0.00202	CbGpPWpGaD
Lansoprazole—Nausea—Irinotecan—colon cancer	0.000114	0.000598	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—ODC1—colon cancer	0.000114	0.00201	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CHST5—colon cancer	0.000114	0.00201	CbGpPWpGaD
Lansoprazole—Back pain—Methotrexate—colon cancer	0.000114	0.000595	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—KRAS—colon cancer	0.000114	0.00201	CbGpPWpGaD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000113	0.002	CbGpPWpGaD
Lansoprazole—Dyspepsia—Capecitabine—colon cancer	0.000113	0.000593	CcSEcCtD
Lansoprazole—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.000112	0.00198	CbGpPWpGaD
Lansoprazole—Decreased appetite—Capecitabine—colon cancer	0.000112	0.000586	CcSEcCtD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	0.000112	0.00197	CbGpPWpGaD
Lansoprazole—Gastrointestinal disorder—Capecitabine—colon cancer	0.000111	0.000582	CcSEcCtD
Lansoprazole—Fatigue—Capecitabine—colon cancer	0.000111	0.000581	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000111	0.00196	CbGpPWpGaD
Lansoprazole—Vision blurred—Methotrexate—colon cancer	0.000111	0.000579	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000111	0.00195	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CA7—colon cancer	0.00011	0.00195	CbGpPWpGaD
Lansoprazole—Pain—Capecitabine—colon cancer	0.00011	0.000576	CcSEcCtD
Lansoprazole—Constipation—Capecitabine—colon cancer	0.00011	0.000576	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	0.00011	0.00194	CbGpPWpGaD
Lansoprazole—Nausea—Fluorouracil—colon cancer	0.000109	0.000573	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—HRAS—colon cancer	0.000109	0.00193	CbGpPWpGaD
Lansoprazole—Ill-defined disorder—Methotrexate—colon cancer	0.000109	0.00057	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—colon cancer	0.000109	0.000568	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000109	0.00192	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—TP53—colon cancer	0.000108	0.0019	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Capecitabine—colon cancer	0.000106	0.000555	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—colon cancer	0.000106	0.000554	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—colon cancer	0.000106	0.000552	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Capecitabine—colon cancer	0.000105	0.000551	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—colon cancer	0.000105	0.00055	CcSEcCtD
Lansoprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—colon cancer	0.000103	0.00181	CbGpPWpGaD
Lansoprazole—Cough—Methotrexate—colon cancer	0.000103	0.000537	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000103	0.00181	CbGpPWpGaD
Lansoprazole—Urticaria—Capecitabine—colon cancer	0.000102	0.000536	CcSEcCtD
Lansoprazole—Body temperature increased—Capecitabine—colon cancer	0.000102	0.000533	CcSEcCtD
Lansoprazole—Abdominal pain—Capecitabine—colon cancer	0.000102	0.000533	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—colon cancer	0.000102	0.000533	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000102	0.00179	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000101	0.00178	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—colon cancer	0.000101	0.00178	CbGpPWpGaD
Lansoprazole—Chest pain—Methotrexate—colon cancer	0.0001	0.000523	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—colon cancer	0.0001	0.000523	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—colon cancer	0.0001	0.000523	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—ODC1—colon cancer	9.96e-05	0.00176	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CHST5—colon cancer	9.96e-05	0.00176	CbGpPWpGaD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	9.93e-05	0.00052	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—colon cancer	9.88e-05	0.000517	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	9.77e-05	0.00172	CbGpPWpGaD
Lansoprazole—Confusional state—Methotrexate—colon cancer	9.67e-05	0.000506	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—AKT1—colon cancer	9.65e-05	0.0017	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	9.6e-05	0.0017	CbGpPWpGaD
Lansoprazole—Anaphylactic shock—Methotrexate—colon cancer	9.59e-05	0.000502	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—colon cancer	9.58e-05	0.00169	CbGpPWpGaD
Lansoprazole—Infection—Methotrexate—colon cancer	9.53e-05	0.000499	CcSEcCtD
Lansoprazole—Hypersensitivity—Capecitabine—colon cancer	9.49e-05	0.000497	CcSEcCtD
Lansoprazole—CYP2C8—Arachidonic acid metabolism—PTGS2—colon cancer	9.42e-05	0.00166	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	9.42e-05	0.00166	CbGpPWpGaD
Lansoprazole—Nervous system disorder—Methotrexate—colon cancer	9.4e-05	0.000492	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—colon cancer	9.39e-05	0.000491	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—colon cancer	9.31e-05	0.000487	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—colon cancer	9.27e-05	0.000485	CcSEcCtD
Lansoprazole—Asthenia—Capecitabine—colon cancer	9.24e-05	0.000484	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—colon cancer	9.14e-05	0.000478	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—colon cancer	9.14e-05	0.00161	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	9.14e-05	0.00161	CbGpPWpGaD
Lansoprazole—Pruritus—Capecitabine—colon cancer	9.11e-05	0.000477	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	9.11e-05	0.00161	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—AKT1—colon cancer	9.09e-05	0.00161	CbGpPWpGaD
Lansoprazole—Hypotension—Methotrexate—colon cancer	8.96e-05	0.000469	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—SRC—colon cancer	8.89e-05	0.00157	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	8.89e-05	0.00157	CbGpPWpGaD
Lansoprazole—Diarrhoea—Capecitabine—colon cancer	8.81e-05	0.000461	CcSEcCtD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	8.75e-05	0.00154	CbGpPWpGaD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—colon cancer	8.74e-05	0.000457	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—colon cancer	8.67e-05	0.000454	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	8.65e-05	0.00153	CbGpPWpGaD
Lansoprazole—Paraesthesia—Methotrexate—colon cancer	8.61e-05	0.000451	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—colon cancer	8.55e-05	0.000447	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—colon cancer	8.55e-05	0.00151	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—AKT1—colon cancer	8.53e-05	0.00151	CbGpPWpGaD
Lansoprazole—Somnolence—Methotrexate—colon cancer	8.53e-05	0.000446	CcSEcCtD
Lansoprazole—Dizziness—Capecitabine—colon cancer	8.52e-05	0.000446	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—colon cancer	8.44e-05	0.000442	CcSEcCtD
Lansoprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—colon cancer	8.41e-05	0.00148	CbGpPWpGaD
Lansoprazole—Decreased appetite—Methotrexate—colon cancer	8.34e-05	0.000436	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—colon cancer	8.28e-05	0.000433	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—colon cancer	8.27e-05	0.000433	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	8.23e-05	0.00145	CbGpPWpGaD
Lansoprazole—Pain—Methotrexate—colon cancer	8.2e-05	0.000429	CcSEcCtD
Lansoprazole—Vomiting—Capecitabine—colon cancer	8.19e-05	0.000429	CcSEcCtD
Lansoprazole—Rash—Capecitabine—colon cancer	8.12e-05	0.000425	CcSEcCtD
Lansoprazole—Dermatitis—Capecitabine—colon cancer	8.11e-05	0.000425	CcSEcCtD
Lansoprazole—Headache—Capecitabine—colon cancer	8.07e-05	0.000422	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—colon cancer	7.96e-05	0.00141	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—TGFB1—colon cancer	7.94e-05	0.0014	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	7.94e-05	0.0014	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Methotrexate—colon cancer	7.9e-05	0.000414	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—colon cancer	7.84e-05	0.00041	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	7.79e-05	0.00137	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	7.79e-05	0.00137	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	7.73e-05	0.00136	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	7.7e-05	0.00136	CbGpPWpGaD
Lansoprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	7.67e-05	0.00135	CbGpPWpGaD
Lansoprazole—Nausea—Capecitabine—colon cancer	7.65e-05	0.0004	CcSEcCtD
Lansoprazole—Urticaria—Methotrexate—colon cancer	7.62e-05	0.000399	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—colon cancer	7.58e-05	0.000397	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—colon cancer	7.58e-05	0.000397	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—CA7—colon cancer	7.47e-05	0.00132	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	7.36e-05	0.0013	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CHST5—colon cancer	7.34e-05	0.0013	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ODC1—colon cancer	7.34e-05	0.0013	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Methotrexate—colon cancer	7.07e-05	0.00037	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	7.01e-05	0.00124	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—PPARG—colon cancer	6.95e-05	0.00123	CbGpPWpGaD
Lansoprazole—Asthenia—Methotrexate—colon cancer	6.88e-05	0.00036	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—CA7—colon cancer	6.84e-05	0.00121	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	6.8e-05	0.0012	CbGpPWpGaD
Lansoprazole—Pruritus—Methotrexate—colon cancer	6.78e-05	0.000355	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—ODC1—colon cancer	6.68e-05	0.00118	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CHST5—colon cancer	6.68e-05	0.00118	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	6.58e-05	0.00116	CbGpPWpGaD
Lansoprazole—Diarrhoea—Methotrexate—colon cancer	6.56e-05	0.000343	CcSEcCtD
Lansoprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	6.55e-05	0.00116	CbGpPWpGaD
Lansoprazole—Dizziness—Methotrexate—colon cancer	6.34e-05	0.000332	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	6.25e-05	0.0011	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	6.12e-05	0.00108	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—AKT1—colon cancer	6.11e-05	0.00108	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CA7—colon cancer	6.11e-05	0.00108	CbGpPWpGaD
Lansoprazole—Vomiting—Methotrexate—colon cancer	6.1e-05	0.000319	CcSEcCtD
Lansoprazole—Rash—Methotrexate—colon cancer	6.05e-05	0.000316	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	6.05e-05	0.00107	CbGpPWpGaD
Lansoprazole—Dermatitis—Methotrexate—colon cancer	6.04e-05	0.000316	CcSEcCtD
Lansoprazole—Headache—Methotrexate—colon cancer	6.01e-05	0.000314	CcSEcCtD
Lansoprazole—ABCB1—Metabolism—CA7—colon cancer	5.96e-05	0.00105	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	5.83e-05	0.00103	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	5.83e-05	0.00103	CbGpPWpGaD
Lansoprazole—Nausea—Methotrexate—colon cancer	5.7e-05	0.000298	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	5.67e-05	0.001	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	5.67e-05	0.001	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CA7—colon cancer	5.62e-05	0.000992	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CA7—colon cancer	5.57e-05	0.000983	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	5.52e-05	0.000974	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	5.47e-05	0.000965	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	5.45e-05	0.000962	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CASP3—colon cancer	5.28e-05	0.000933	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	5.18e-05	0.000914	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	5.08e-05	0.000896	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	5.06e-05	0.000894	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	5.04e-05	0.00089	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	4.97e-05	0.000877	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	4.97e-05	0.000877	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	4.86e-05	0.000857	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CA7—colon cancer	4.76e-05	0.00084	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.71e-05	0.000831	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	4.69e-05	0.000828	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	4.69e-05	0.000828	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—EP300—colon cancer	4.55e-05	0.000803	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CHST5—colon cancer	4.52e-05	0.000798	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ODC1—colon cancer	4.52e-05	0.000798	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—VEGFA—colon cancer	4.48e-05	0.000792	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	4.45e-05	0.000786	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CHST5—colon cancer	4.15e-05	0.000732	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ODC1—colon cancer	4.15e-05	0.000732	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—TGFB1—colon cancer	4.12e-05	0.000727	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	3.99e-05	0.000704	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—ABCB1—colon cancer	3.77e-05	0.000665	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.7e-05	0.000653	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CHST5—colon cancer	3.7e-05	0.000653	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ODC1—colon cancer	3.7e-05	0.000653	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.7e-05	0.000653	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CA7—colon cancer	3.67e-05	0.000648	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ODC1—colon cancer	3.61e-05	0.000638	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CHST5—colon cancer	3.61e-05	0.000638	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ODC1—colon cancer	3.4e-05	0.000601	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CHST5—colon cancer	3.4e-05	0.000601	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ODC1—colon cancer	3.37e-05	0.000596	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CHST5—colon cancer	3.37e-05	0.000596	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	3.3e-05	0.000583	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.08e-05	0.000543	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	3.07e-05	0.000541	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.03e-05	0.000535	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ABCB1—colon cancer	3.01e-05	0.000532	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—TYMS—colon cancer	2.96e-05	0.000522	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CHST5—colon cancer	2.88e-05	0.000509	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ODC1—colon cancer	2.88e-05	0.000509	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.81e-05	0.000496	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ABCB1—colon cancer	2.63e-05	0.000465	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.61e-05	0.00046	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—TYMS—colon cancer	2.59e-05	0.000456	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.54e-05	0.000448	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.51e-05	0.000444	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.46e-05	0.000433	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.39e-05	0.000421	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.34e-05	0.000412	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.28e-05	0.000402	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.27e-05	0.000401	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CHST5—colon cancer	2.23e-05	0.000393	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ODC1—colon cancer	2.23e-05	0.000393	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.21e-05	0.000391	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PPARG—colon cancer	2.1e-05	0.00037	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.04e-05	0.000359	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.03e-05	0.000359	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.99e-05	0.000352	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.98e-05	0.00035	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ABCB1—colon cancer	1.94e-05	0.000343	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—TYMS—colon cancer	1.91e-05	0.000336	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.88e-05	0.000332	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.87e-05	0.00033	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PPARG—colon cancer	1.83e-05	0.000323	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ABCB1—colon cancer	1.77e-05	0.000312	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—TYMS—colon cancer	1.73e-05	0.000306	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.73e-05	0.000305	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.71e-05	0.000302	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.67e-05	0.000295	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTGS2—colon cancer	1.65e-05	0.000291	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.53e-05	0.00027	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.47e-05	0.000259	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.47e-05	0.000259	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTGS2—colon cancer	1.44e-05	0.000254	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.41e-05	0.000249	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.39e-05	0.000246	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—EP300—colon cancer	1.37e-05	0.000242	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPARG—colon cancer	1.35e-05	0.000238	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.35e-05	0.000238	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPARG—colon cancer	1.23e-05	0.000217	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.22e-05	0.000216	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.2e-05	0.000212	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—EP300—colon cancer	1.2e-05	0.000212	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ABCB1—colon cancer	1.2e-05	0.000211	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.19e-05	0.00021	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—TYMS—colon cancer	1.17e-05	0.000207	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.12e-05	0.000198	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.1e-05	0.000193	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ABCB1—colon cancer	1.1e-05	0.000193	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TYMS—colon cancer	1.08e-05	0.00019	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—colon cancer	1.06e-05	0.000187	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—colon cancer	1.01e-05	0.000179	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	1e-05	0.000176	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ABCB1—colon cancer	9.78e-06	0.000173	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—colon cancer	9.66e-06	0.000171	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TYMS—colon cancer	9.61e-06	0.00017	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TYMS—colon cancer	9.38e-06	0.000165	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	9.37e-06	0.000165	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.12e-06	0.000161	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.04e-06	0.00016	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ABCB1—colon cancer	9e-06	0.000159	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ABCB1—colon cancer	8.92e-06	0.000157	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—colon cancer	8.86e-06	0.000156	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TYMS—colon cancer	8.84e-06	0.000156	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—EP300—colon cancer	8.83e-06	0.000156	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TYMS—colon cancer	8.76e-06	0.000155	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPARG—colon cancer	8.32e-06	0.000147	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.28e-06	0.000146	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—colon cancer	8.28e-06	0.000146	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—EP300—colon cancer	8.04e-06	0.000142	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.79e-06	0.000137	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPARG—colon cancer	7.62e-06	0.000135	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ABCB1—colon cancer	7.62e-06	0.000135	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TYMS—colon cancer	7.48e-06	0.000132	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.39e-06	0.000131	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—colon cancer	7.24e-06	0.000128	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPARG—colon cancer	6.8e-06	0.00012	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.74e-06	0.000119	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPARG—colon cancer	6.64e-06	0.000117	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—colon cancer	6.54e-06	0.000115	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—colon cancer	6.54e-06	0.000115	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPARG—colon cancer	6.26e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPARG—colon cancer	6.2e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—colon cancer	6e-06	0.000106	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—colon cancer	5.95e-06	0.000105	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCB1—colon cancer	5.88e-06	0.000104	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TYMS—colon cancer	5.78e-06	0.000102	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.76e-06	0.000102	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—EP300—colon cancer	5.44e-06	9.6e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—colon cancer	5.35e-06	9.45e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—colon cancer	5.34e-06	9.42e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPARG—colon cancer	5.3e-06	9.36e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—colon cancer	5.22e-06	9.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—EP300—colon cancer	4.99e-06	8.8e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—colon cancer	4.92e-06	8.69e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—colon cancer	4.88e-06	8.62e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—colon cancer	4.86e-06	8.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—EP300—colon cancer	4.45e-06	7.86e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—EP300—colon cancer	4.35e-06	7.67e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—colon cancer	4.17e-06	7.36e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—EP300—colon cancer	4.09e-06	7.23e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPARG—colon cancer	4.09e-06	7.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—EP300—colon cancer	4.06e-06	7.17e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—colon cancer	4.02e-06	7.1e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—colon cancer	3.69e-06	6.51e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—EP300—colon cancer	3.47e-06	6.12e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—colon cancer	3.29e-06	5.81e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—colon cancer	3.29e-06	5.8e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—colon cancer	3.22e-06	5.68e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—colon cancer	3.21e-06	5.67e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—colon cancer	3.03e-06	5.35e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—colon cancer	3.01e-06	5.32e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—colon cancer	3e-06	5.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—colon cancer	2.69e-06	4.75e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—EP300—colon cancer	2.68e-06	4.73e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—colon cancer	2.63e-06	4.64e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—colon cancer	2.57e-06	4.53e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—colon cancer	2.47e-06	4.37e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—colon cancer	2.45e-06	4.33e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—colon cancer	2.1e-06	3.7e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—colon cancer	1.98e-06	3.5e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—colon cancer	1.62e-06	2.86e-05	CbGpPWpGaD
